AACR-NCI-EORTC 2017: Potential Novel Agent for Estrogen Receptor–Positive Breast Cancer
By: Susan Reckling
Posted: Friday, November 3, 2017
EC-372, an investigational selective estrogen receptor degrader, has shown anticancer activity and may prove to be a novel therapeutic agent in the treatment of estrogen receptor–positive breast cancer, according to Pradeep Chaluvally-Raghavan, PhD, of the Medical College of Wisconsin, Milwaukee, and colleagues. These findings, which reportedly represent the first comprehensive study focusing on the mechanism by which EC-372 inhibits tumor growth and promotes apoptosis of human breast cancer cells, were presented at the American Association for Cancer Research–National Cancer Institute–European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia (Abstract A195). Studies to evaluate the potential of EC-372 on in vivo tumor growth and metastasis are ongoing.
The investigators reported that EC-372 inhibited the growth of T47D and MCF-7 human breast cancer cells. In both cell lines, this agent induced cell shrinkage and apoptotic bodies. In addition, treatment with EC-372 appeared to downregulate the levels of estrogen receptor-alpha and progesterone receptor as well as stabilized the levels of estrogen receptor-beta, which resulted in cell-cycle arrest, apoptosis, and suppressed growth of breast cancer cells.